Science
Praveen Kumar Marimuthu: Neoadjuvant dostarlimab for Stage I–III dMMR solid tumors
Praveen Kumar Marimuthu/X

Praveen Kumar Marimuthu: Neoadjuvant dostarlimab for Stage I–III dMMR solid tumors

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an article by Andrea Cercek, et al. on X:

“Nonoperative Rx of d-MMR tumors NEJM:

Neoadjuvant dostarlimab (500 mg q3w x 6 mo) for Stage I–III dMMR solid tumors (rectal and non-rectal):

  • 4/5 had cCR.
  • 4/5 avoided surgery.
  • 2-yr RFS 92%.
  • No Rx-related deaths.

For prostate, GE.”

Praveen Kumar Marimuthu: Neoadjuvant dostarlimab for Stage I–III dMMR solid tumors

Nonoperative Management of Mismatch Repair–Deficient Tumors.

Journal: The New England Journal of Medicine

Authors: Andrea Cercek, et al.

Praveen Kumar Marimuthu: Neoadjuvant dostarlimab for Stage I–III dMMR solid tumors

More posts featuring Praveen Kumar Marimuthu.

Andrea Cercek cancer Christian Medical College and Hospital fight against cancer Global fight against cancer NEJM neoadjuvant dostarlimab OncoDaily Oncology Praveen Kumar Marimuthu The New England Journal of Medicine.